Observational Study to Evaluate the Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Trial Profile

Observational Study to Evaluate the Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Autologous stem cell therapy (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors EHL Bio
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 Sep 2022 to 19 Sep 2022.
    • 22 Sep 2017 Planned primary completion date changed from 1 Sep 2022 to 19 Sep 2022.
    • 23 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top